查看完整行情页>>

|

货币单位:美元(USD)

诺华公司

Novartis AG (nvs)

实时(?):
盘后(?):
读取中...
  • -- (--%)
开盘价:-- 最高价:-- 最低价:-- 52周最高价:-- 52周最低价:--
成交量:-- 平均成交量:-- 市值:-- 市盈率:-- 预期市盈率:--
每股收益:-- 贝塔系数:-- 股息:-- 收益率:-- 总股本:--
Vasant Narasimhan Vasant Narasimhan is a businessperson who has been at the helm of 8 different companies. Currently, Dr. Narasimhan is Chief Executive Officer for Novartis AG and Chief Executive Officer at Novartis International AG, Chief Executive Officer for Novartis Pharmaceuticals Corp., Chief Executive Officer of Novartis Korea Co., Ltd. and Chief Executive Officer for Novartis Pharma BV (which are all subsidiaries of Novartis AG). He is also on the board of Pharmaceutical Research & Manufacturers of America (former Chairman) and Novartis Foundation and Chairman of African Parks Network and Member of National Academy of Medicine (United States). In the past Vasant Narasimhan held the position of Global Head-Development at Novartis Vaccines & Diagnostics, Inc., Global Head-Biopharmaceuticals at Sandoz International GmbH, Global Head-Development at Novartis Pharmaceuticals and Global Head-Development at Sandoz Pharmaceuticals AG. He received a doctorate from Harvard Medical School, a graduate degree from Harvard Kennedy School of Government and an undergraduate degree from The University of Chicago.
Shreeram Aradhye Currently, Shreeram Aradhye occupies the position of Chief Medical Officer & President-Development at Novartis AG. He is also on the board of Valo Health LLC. Dr. Aradhye previously held the position of Independent Director at Axcella Health, Inc., Chief Medical Officer & Executive Vice President at Dicerna Pharmaceuticals, Inc., Head-Global Clinical Development & Medical Affairs at Sandoz International GmbH, Chief Medical Officer at Novartis Pharmaceuticals Corp. and Assistant Professor at the University of Pennsylvania. Shreeram Aradhye received an undergraduate degree from All India Institute of Medical Sciences.
Robert Kowalski Presently, Robert Kowalski is Chief People & Organization Officer at Novartis AG. In the past he was President of Novartis Corp., Executive VP & Global Head-Regulatory Affairs at Novartis Pharmaceuticals Corp. and Senior Vice President & Head-Regulatory Affairs at Novartis Pharma AG. Robert Kowalski received an undergraduate degree and a doctorate from the University of Wisconsin.
Kees Roks Kees Roks occupies the position of Chief Audit Officer at Novartis AG. Mr. Roks is also on the board of Junior Achievement Europe. He received an undergraduate degree from Technische Universiteit Eindhoven.
Karen L. Hale Currently, Karen L. Hale holds the position of Chief Legal Officer at Novartis AG. She is also Member of Illinois State Bar Association and Member of The Virginia Bar Association. She previously occupied the position of Divisional VP-Commercial Litigation at Abbott Laboratories, Vice President & Deputy General Counsel at AbbVie, Inc. and Associate Attorney at Sidley & Austin. She received an undergraduate degree from Duke University and a graduate degree from The College of William & Mary.
Harry Werner Kirsch Presently, Harry Werner Kirsch is Chief Financial Officer for Novartis AG. Mr. Kirsch is also on the board of Novartis International AG, Novartis Vaccines & Diagnostics, Inc., Novartis Institutes for Biomedical Research, Inc. and Novartis Pharma KK. In his past career Mr. Kirsch held the position of CFO-Global Pharmaceutical Business at Procter & Gamble Co. He received an undergraduate degree from Karlsruher Institut für Technologie.
Hans Jörg Reinhardt Hans Jörg Reinhardt is a German businessperson who has been at the head of 13 different companies and currently is Chairman for Novartis AG, Chairman of Novartis, Inc., Chairman-Supervisory Board of Novartis International AG, Chairman of Novartis Pharmaceuticals Corp., Chairman of Novartis Finance Corp, Chairman of Novartis Institutes for Biomedical Research, Inc., Chairman at Novartis Pharma AG, Chairman for Abadia Retuerta SA and Chairman of Novartis Pharma BV (which are all subsidiaries of Novartis AG) and Chairman-Trustees Board at Institut für molekulare und klinische Ophthalmologie Basel. Hans Jörg Reinhardt is also on the board of Swiss Re AG and Chairman at Novartis Foundation, Council Member at International Federation of Pharmaceutical Manufacturers and Member of Helmholtz-Gemeinschaft Deutscher Forschungszentren eV. In his past career he held the position of Chief Operating Officer of Novartis AG Chairman of Novartis Institute for Functional Genomics, Inc. and Head-Development at Sandoz Pharmaceuticals AG (both are subsidiaries of Novartis AG) and Chairman-Management Board at Bayer HealthCare AG. Hans Jörg Reinhardt received a doctorate from Universität des Saarlandes.
Aharon Gal Presently, Aharon Gal is Senior Analyst at Sanford C. Bernstein & Co. LLC. Dr. Gal is also Chief Strategy & Growth Officer at Novartis AG. In the past Dr. Gal held the position of Manager at The Boston Consulting Group, Inc. and Vice President for Canon U.S. Life Sciences, Inc. Dr. Gal received a doctorate from Massachusetts Institute of Technology and an undergraduate degree from Emory University.
Klaus Moosmayer Presently, Klaus Moosmayer occupies the position of Chief Ethics, Risk & Compliance Officer at Novartis AG. Dr. Moosmayer is also on the board of SwissHoldings and Member-Executive Board at Organisation for Economic Co-Operation & Development. Dr. Moosmayer previously occupied the position of Chief Compliance Officer at Siemens AG. Dr. Moosmayer received a graduate degree from the University of Freiburg.
Simon Brown Simon Brown holds the position of Venture Partner at Emerge Venture Lab Ltd. Mr. Brown is also Chief Learning Officer at Novartis AG. He received an undergraduate degree from Royal Holloway University of London.
James E. Bradner James E. Bradner is an American entrepreneur who founded 5 companies, which include: C4 Therapeutics, Inc., Syros Pharmaceuticals, Inc. and Acetylon Pharmaceuticals, Inc. Currently, he is Chief Scientific Officer for Amgen, Inc., Advisor at Longwood Fund Management LLC and Chairman at Novartis Institute for Functional Genomics, Inc. Dr. Bradner is also on the board of Foundation for the National Institutes of Health, Inc. and Associate Professor at Harvard Medical School. In his past career he occupied the position of Associate Director-Therapeutics Science Centre at The Broad Institute, Inc., President at Novartis Institutes for Biomedical Research, Inc., Member of American Chemical Society, Member of American Society of Hematology, Director at Acetylon Pharmaceuticals, Inc., Director at TetraLogic Research & Development Corp. and Director at Syros Pharmaceuticals, Inc. James E. Bradner received an undergraduate degree from Harvard University and a doctorate from Pritzker School of Medicine.
Steffen Lang Steffen Lang is on the board of Bachem Holding AG and President-Operations at Novartis AG. Dr. Lang received a doctorate from Swiss Federal Institute of Technology and a graduate degree from Ruprecht-Karls-Universität Heidelberg.
Patrick Horber Patrick Horber is Managing Director at AbbVie Pharmaceuticals GmbH. Dr. Horber is also President-International at Novartis AG. In his past career Dr. Horber occupied the position of Co-Managing Director at AbbVie Deutschland GmbH & Co. KG. Dr. Horber received a graduate degree from the University of Zurich.